Biotest Facility
Biotest Facility ApS is a CRO that offers services focused on preclinical in vivo pharmacology. Biotest Facility is supporting the early preclinical phase of drug development by testing the pharmacokinetics, toxicity, and efficacy of drug candidates by using rodent research models. Biotest Facility supports the formulation and administration of a range of drug classes, from the small chemical manufactured molecule to large biologics such as drug-conjugated antibodies. We have the expertise to handle hazardous material as disease inducing agents, cytotoxic cancer compounds, radioactive tracers and radiopharmaceuticals.
Pharmacokinetics and biodistribution
Indications of toxicity and determination of the pharmacokinetic profile of the drug candidate are key points in the early preclinical phase to evaluate the druggability before testing the proof-of-concept in the relevant disease model. Together with technical partners, Biotest Facility is providing a service package including bioanalyses, calculations and simulations based on the analytical readouts.
Efficacy testing
The aim of this service is to test the proof-of-concept of a new therapy or drug candidate. Biotest Facility offers studies with disease models in rodents. These models are rodent strains that are genetically predisposed for a disease that is induced by a chemical substance, immune-reactive treatment, surgery or by a special diet. Careful design and planning of the preclinical studies and tests, combined with robust experimental models, ensures that the pharmacological and translational questions are solved efficiently.
Cancer disease models in mice are our special expertise
We have over ten years of experience with xenograft studies, including several variations of the model, eg subcutaneous, intravascular (disseminated) and orthotopic inoculation of the cancer cells. These studies include careful selection of the ideal host animal strain for the specific donor cancer cells, which can be either cultured cancer cell lines (CDX) or tumor tissue from patients (PDX). Immunooncology (I-O) models are offered as syngeneic models of mouse tumor cells inoculated in mouse.
Cell culture assay
Culturing and expansion of human tumor cells for inoculations are mandatory for most of our cancer models, and cells culture assays are also used to validate the drug target in advance of testing in rodents and to assays the potency of a drug candidate. In all animal research models, we aim to combine the testing in rodents with the matching cells culture assay if it is available.
Animal facility
At Biotest Facility we aim to have a fully upgraded animal facility to meet both the requirement and condition for scientific accuracy and high standards for animal welfare. Biotest Facility is committed to the continuous implementation of the principles of the 3Rs (Replacement, Reduction, and Refinement) in animal experimentation.
Biotest Facility is a 100% independent CRO with a focus on the early preclinical in vivo phase, but also having cooperation with technical partners to offer extended service and accelerate the drug discovery process. We aim to have an integrated process to generate the optimal basis for decision making regarding the further drug development process. We are looking forward to conducting studies with your new drug candidate.
